Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP:PHRRF)

0.0819 -0.0075 (-8.39%)
Streaming Delayed Price Updated: 1:35 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 746,040
Open 0.0962
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0894
Today's Range 0.0756 - 0.0962
52wk Range 0.0850 - 0.5500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a... 
Via Newsfile
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life... 
Via Newsfile
Topics Intellectual Property

Performance

YTD
-46.8%
-46.8%
1 Month
-69.2%
-69.2%
3 Month
-76.2%
-76.2%
6 Month
-41.0%
-41.0%
1 Year
-59.0%
-59.0%

More News

Read More
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Via Newsfile
Topics Artificial Intelligence
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease
Via Newsfile
Topics Intellectual Property
PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
Via Newsfile
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative
Via Newsfile
Topics Death
PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))
Via Newsfile
PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))
Via Newsfile
PharmaTher Announces FDA Approval of Ketamine (KETARx™)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Receives US FDA Approval Goal Date for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
Via Newsfile
PharmaTher Provides Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher CEO Issues Letter to Shareholders
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Pharmather Hldgs Ltd publicly traded?
Yes, Pharmather Hldgs Ltd is publicly traded.
What exchange does Pharmather Hldgs Ltd trade on?
Pharmather Hldgs Ltd trades on the OTC Traded
What is the ticker symbol for Pharmather Hldgs Ltd?
The ticker symbol for Pharmather Hldgs Ltd is PHRRF on the OTC Traded
What is the current price of Pharmather Hldgs Ltd?
The current price of Pharmather Hldgs Ltd is 0.0819
When was Pharmather Hldgs Ltd last traded?
The last trade of Pharmather Hldgs Ltd was at 10/23/25 01:35 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.